全文获取类型
收费全文 | 12939篇 |
免费 | 916篇 |
国内免费 | 69篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 259篇 |
妇产科学 | 185篇 |
基础医学 | 1893篇 |
口腔科学 | 109篇 |
临床医学 | 1796篇 |
内科学 | 3217篇 |
皮肤病学 | 253篇 |
神经病学 | 1134篇 |
特种医学 | 554篇 |
外国民族医学 | 3篇 |
外科学 | 1938篇 |
综合类 | 36篇 |
一般理论 | 6篇 |
预防医学 | 576篇 |
眼科学 | 197篇 |
药学 | 859篇 |
中国医学 | 22篇 |
肿瘤学 | 811篇 |
出版年
2023年 | 82篇 |
2022年 | 131篇 |
2021年 | 397篇 |
2020年 | 209篇 |
2019年 | 323篇 |
2018年 | 388篇 |
2017年 | 268篇 |
2016年 | 278篇 |
2015年 | 357篇 |
2014年 | 496篇 |
2013年 | 631篇 |
2012年 | 1019篇 |
2011年 | 1106篇 |
2010年 | 553篇 |
2009年 | 534篇 |
2008年 | 820篇 |
2007年 | 834篇 |
2006年 | 800篇 |
2005年 | 772篇 |
2004年 | 702篇 |
2003年 | 667篇 |
2002年 | 633篇 |
2001年 | 175篇 |
2000年 | 168篇 |
1999年 | 149篇 |
1998年 | 131篇 |
1997年 | 109篇 |
1996年 | 85篇 |
1995年 | 56篇 |
1994年 | 51篇 |
1993年 | 57篇 |
1992年 | 97篇 |
1991年 | 84篇 |
1990年 | 68篇 |
1989年 | 75篇 |
1988年 | 76篇 |
1987年 | 64篇 |
1986年 | 63篇 |
1985年 | 55篇 |
1984年 | 38篇 |
1983年 | 37篇 |
1982年 | 25篇 |
1981年 | 21篇 |
1980年 | 24篇 |
1979年 | 19篇 |
1978年 | 19篇 |
1976年 | 17篇 |
1975年 | 28篇 |
1973年 | 18篇 |
1967年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
991.
Lesimple T Hassel MB Gédouin D Seigneuret E Carsin B Hamlat A Riffaud L Simon H Malhaire JP Guégan Y 《Journal of neuro-oncology》2003,65(2):141-148
A phase I study was performed to determine the maximum tolerated dose and the recommended dose of continuous intravenous infusion of topotecan in combination with radiotherapy (RT) in patients with previously untreated glioblastoma multiforme (GBM). Twenty patients with histologically proven GBM and 1 with rhabdoid tumor were enrolled. After surgery or stereotactic biopsy, patients received cranial RT (60 Gy/30 fractions/40 days) and 3 cycles of topotecan as continuous infusion (CIV) from day 1 to 5 on weeks 1, 3, and 5 during RT. The dose of topotecan was escalated from 0.6 to 1.0 mg/m2/day. Four dose levels were tested. One grade 4 thrombocytopenia was seen at level 1 (topotecan dose 0.6 mg/m2/day; 6 patients). No dose-limiting toxicity was seen at level 2 (0.8 mg/m2/day; 3 patients) or an intermediate level of 2 bis (0.9 mg/m2/day; 6 patients). Six patients were included at level 3 (1.0 mg/m2/day), 4 of whom experienced dose-limiting toxicities, including 3 episodes of grade 4 thrombocytopenia, 1 platelet transfusion, 1 febrile neutropenia, and 1 grade 4 neutropenia of more than 7 days. Eighty percent of patients with GBM were alive at 12 months. The dose-limiting toxicity of topotecan administered as CIV for 5 days every 2 weeks is hematological. The maximum tolerated dose is 1.0 mg/m2/day and the recommended dose is 0.9 mg/m2/day. A phase II trial using the recommended dose of topotecan is ongoing. 相似文献
992.
CKI p21 is a regulator of cellular responses to microtubule damage induced by drugs such as paclitaxel (PTX). It mediates the G1 4N arrest postactivation of the spindle assembly checkpoint and protects cancer cells against PTX-induced cytotoxicity. We demonstrated here that low doses of PTX that are unable to activate the spindle assembly checkpoint, upregulate p21 by a p53-dependent pathway and induce its translocation to the cytoplasm. This cytoplasmic accumulation of p21 resulted from an AKT-dependent p21 phosphorylation leading to an association of p21 with 14-3-3. Furthermore, the cytoplasmic p21 accumulation observed in PTX-treated cells was inhibited by LY 294002, a specific PI-3 kinase inhibitor or by the expression of a dominant-negative AKT mutant. However, the kinase activity of AKT was unchanged in PTX-treated cells, suggesting that low doses of PTX could regulate p21 phosphorylation via inhibition of its dephosphorylation. As a functional consequence, we found that cytoplasmic accumulation of the phosphorylated form of p21 prevents the inhibitory effect of p21, enabling these cells to escape to the p53-dependent Gl/S and G2/M checkpoints. 相似文献
993.
Trempat P Villalva C Laurent G Armstrong F Delsol G Dastugue N Brousset P 《Oncogene》2003,22(36):5702-5706
Two cases of atypical chronic myeloid leukaemia (CML) carrying the t(4;22)(q12;q11) translocation involving the breakpoint cluster region (BCR) and platelet-derived growth factor alpha receptor (PDGFRA) genes have been recently characterized. We report a third case of atypical CML with the same translocation but with a distinct breakpoint fusing BCR exon 1 with PDGFRA exon 13. The patient had a clinical presentation of CML with progressive transformation in B-cell acute lymphoblastic leukaemia. The involvement of PDGFRA led us to treat the patient with the small organic compound imatinib mesylate/STI571 (Glivec) that blocks the ATP binding site of tyrosine kinases such as Abelson, KIT and platelet-derived growth factor receptors. The patient subsequently achieved a rapid clinical and molecular response clearly demonstrating, for the first time, that Glivec is active against PDGFRA in vivo. Therefore, our study expands the list of Glivec targets and has direct biological and also clinical implications. 相似文献
994.
Rostaing-Rigattieri S Rousselot H Krakowski I Theobald S Collin E Vuillemin N Balp L Torloting G Fergane B Richard B Duclos R Eschalier A Delorme T Minello C Toussaint S Richard A Magnet M Chvetzoff G Larue F Navez ML Collard O Bonnefoi MP Couturier M Santolaria N Wagner JP Fabre N 《Bulletin du cancer》2003,90(8-9):795-806
995.
Frappaz D Chinot O Bataillard A Ben Hassel M Capelle L Chanalet S Chatel M Figarella-Branger D Guegan Y Guyotat J Khé HX Jouanneau E Keime-Guibert F Laforêt C Linassier C Loiseau H Menel P Rousmans S Sanson M Sunyach MP 《Bulletin du cancer》2003,90(10):873-886
CONTEXT: The "Standards, Options and Recommendations" (SOR) project, which started in 1993, is a collaboration between the Federation of French Cancer Centers (FNCLCC), the 20 French Regional Cancer Centers, and specialists from French public universities, general hospitals and private clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients. OBJECTIVE: To define clinical practice guidelines for the management of adult patients with intracranial glioma in collaboration with the Association of French-speaking Neuro-oncologists (Anocef) and the French society of neurosurgeons (SNCLF). These recommendations cover diagnosis, classification, treatment and follow-up of patients with these tumors. METHOD: The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts who define the CPGs according to the definitions of the Standards, Options and Recommendations project. Once the guidelines has been defined, the document is submitted for review by independent reviewers. RESULTS: This article is a summary version of the full document presenting the clinical practice guidelines with algorithms. The main recommendations concern the place of the surgery, radiotherapy, chemiotherapy, imagery and concomitant medical treatments in the specific treatment strategy of grade III and IV glioma, grade II glioma, gliomatosis cerebri, pilocytic astrocytoma, subependymoma, xanthoastrocytoma, intracranial ependymoma and brain stem glioma. 相似文献
996.
997.
Larghero J Leguay T Mourah S Madelaine-Chambrin I Taksin AL Raffoux E Bastie JN Degos L Berthaud P Marolleau JP Calvo F Chomienne C Mahon FX Rousselot P 《Biochemical pharmacology》2003,66(10):1907-1913
The Abl tyrosine kinase inhibitor imatinb is becoming a standard for the treatment of chronic myelogenous leukemia (CML). However, Bcr-Abl gene mutations have been reported mainly in relapsing or resistant patients. In primary resistant patients, only few mutations have been documented so far, suggesting alternative mechanisms. We aimed to investigate if alpha 1 acid glycoprotein (AGP), an acute phase drug binding protein, could be a biological marker for pharmacological resistance to imatinib in nine patients in acute phase CML. All patients (3/3) with high AGP dosages (2.31+/-0.17 mg/mL; normal values, 0.5-1.3mg/mL) were primary resistant to imatinib whereas an early clinical response was observed for the six patients with normal AGP levels (1.13+/-0.2mg/mL). No mutation in the adenosine triphosphate domain of Abl were detected before the initiation of imatinib therapy. By using in vitro tests combining various imatinib concentrations (1-10 microM) with purified human AGP (1 and 3 mg/mL), we demonstrate that imatinib-induced apoptosis of K562 or fresh leukemic CML cells is abrogated or reduced. The same effect was observed using sera from donors with high AGP levels (1.9-3.28 mg/mL). In patients with CML in blastic phase, AGP levels could reflect pharmacological resistance to imatinib, suggesting that increased dosage of imatinib or the use of a competitor to drug binding should be recommended to optimize the therapeutic effect of the drug. 相似文献
998.
Verstuyft C Schwab M Schaeffeler E Kerb R Brinkmann U Jaillon P Funck-Brentano C Becquemont L 《European journal of clinical pharmacology》2003,58(12):809-812
BACKGROUND: The effect of MDR1 C3435T single nucleotide polymorphism (SNP) in exon 26 on digoxin pharmacokinetics has recently been challenged. OBJECTIVE. To clarify the relationships between MDR1 genetic polymorphisms in exon 26 (C3435T) and 21 (G2677T/A) and digoxin pharmacokinetics. MATERIALS AND METHODS: MDR1 genotypes for C3435T and G2677T/A SNPs were determined in 32 healthy subjects whose single oral dose digoxin pharmacokinetics had been measured over 48 h. RESULTS: A significant relationship was observed between C3435T SNP and digoxin AUCs ( p<0,05). Homozygous TT subjects had 20% higher digoxin plasma concentrations than CT and CC subjects and a trend for higher 48 h digoxin urinary recoveries (TT>CT>CC). Similar results, although not statistically significant, were observed from the MDR1 G2677T/A SNP. CONCLUSIONS: Our results confirm that the MDR1 C3435T single nucleotide polymorphism (SNP) significantly affects digoxin disposition kinetics, with homozygous TT subjects presenting the highest plasma concentrations. 相似文献
999.
Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives 总被引:2,自引:0,他引:2
Chauffert B Favoulet P Polycarpe E Duvillard C Beltramo JL Bichat F Rat P Genne P Benoit L 《Surgical Oncology Clinics of North America》2003,12(3):835-848
By decreasing drug drainage through the peritoneal and tumoral vascular networks, epinephrine increases the penetration of cisplatin and oxaliplatin into the metastatic peritoneal tumor nodules. This improved drug penetration increases their antitumor efficacy, allowing the cure of millimetric-sized peritoneal tumor nodules that could not be obtained with cisplatin or oxaliplatin used alone. However, limited drug diffusion into supramillimetric nodules did not result in curing advanced peritoneal carcinomatosis, unless complete resection of macroscopic localized tumor nodules is performed before intraperitoneal chemotherapy. In our opinion, the intraperitoneal epinephrine-cisplatin combination should be clinically assessed in completely or almost completely surgically resected peritoneal carcinomatosis with the objective of preventing recurrent tumors. Due to its reduced toxicity, repeated courses of intraperitoneal oxaliplatin associated with epinephrine could be an interesting alternative to cisplatin for the unresectable disease. 相似文献
1000.
Irinotecan (CPT-11) is a prodrug that is used to treat metastatic colorectal cancer. It is activated to the topoisomerase poison SN-38 by carboxylesterases. SN-38 is subsequently metabolised to its inactive glucuronide, SN-38G, which can however be reactivated to SN-38 by beta-glucuronidase. The purpose of this study was to examine the role of carboxylesterases and beta-glucuronidase in the in vitro production of SN-38 in human colorectal tumours. The production of SN-38 from CPT-11 and SN-38G was measured by HPLC in human colorectal tumour homogenates. Carboxylesterase and beta-glucuronidase activities were found to be lower in tumour tissues compared to matched normal colon mucosa samples. In colorectal tumour, beta-glucuronidase and carboxylesterase-mediated SN-38 production rates were comparable at clinically relevant concentrations of SN-38G and CPT-11, respectively. Therefore, tumour beta-glucuronidase may play a significant role in the exposure of tumours to SN-38 in vivo, particularly during prolonged infusions of CPT-11. 相似文献